Oncologist Interview Questions
& Model Answers, 2026

Be explicit with yourself first about whether the aim is cure, prolongation of life, or symptom control, then say it plainly to the patient in those terms. Establish what they already understand and how much detail they want, give prognosis in ranges with honesty about uncertainty, and document the intent in the record so the whole team is aligned. Patients who do not know their treatment is palliative make choices they would not otherwise make, and interviewers ask this because it is the commonest failure in the specialty.

Order the testing that will change the decision, and order it early enough that results arrive before treatment must start — tissue adequacy is the usual failure point, so involve pathology at biopsy planning. Targetable alterations and immunotherapy predictive markers can move a patient from cytotoxic chemotherapy to targeted or immune therapy with a materially different outcome and toxicity profile. Say how you handle a delayed result in a symptomatic patient and when you would start and switch.

Treat as immune-related colitis until proven otherwise: grade the severity, exclude infection including Clostridioides difficile, and start corticosteroids at a dose matched to the grade rather than waiting. Hold the immunotherapy, escalate to infliximab or vedolizumab for steroid-refractory disease, involve gastroenterology, and taper slowly over weeks. Say that anti-motility agents alone are the wrong reflex and that delayed steroid initiation is what turns a manageable toxicity into a life-threatening one.

This is a time-critical emergency: cultures and broad-spectrum antibiotics within the first hour without waiting for the neutrophil count, fluid resuscitation, source assessment including line infection, and risk stratification for admission versus ambulatory management. Then review the regimen for dose reduction or growth factor support, and educate the patient and family on the fever threshold and the direct contact route. A patient told to call the clinic in the morning is the case that gets reviewed.

Distinguish curative from palliative intent: in a curative setting, dose intensity matters and you support the patient through it with growth factors, antiemetics and monitoring before reducing. In a palliative setting, quality of life dominates and reducing or delaying is often the right choice. Base it on graded toxicity, performance status, organ function and the patient's own account of tolerability, and document the reasoning rather than reducing by habit.

Build screening into the pathway so eligibility is checked at diagnosis rather than after failure, know the open portfolio, and involve the research team early. Discuss it as one option among others with genuine equipoise, explain randomisation and placebo-controlled design honestly, cover the extra visits and testing burden, and make clear that declining does not affect their care. Say how you handle a patient who wants a trial they are not eligible for.

Present the case with staging, performance status, comorbidity and patient preference, propose a plan with the evidence behind it, and be open to challenge from surgery, radiation oncology, radiology and pathology. Then implement what is agreed or document the reasoning if the patient's circumstances change the plan. Say how you handle disagreement, because a tumour board that never disagrees is not functioning.

Give a real conversation: how you prepared, checked what they knew, gave a warning shot, delivered it plainly without jargon, allowed silence, responded to the emotion before giving detail, and arranged follow-up. Oncology interviews weight this as heavily as clinical knowledge, and vague references to a communication framework without a real case do not satisfy panels.

Whether they wanted more treatment than you thought helpful or refused something you thought valuable, describe how you gave complete information, explored the values behind the choice, offered a second opinion, and continued to care for them. Say what you would not do, which is treat to avoid a conversation.

Oncologists lose patients continuously. Describe what you actually do — team debriefs, supervision, boundaries, colleagues — rather than claiming it does not affect you. Groups are assessing sustainability because burnout drives turnover in this specialty.

Time to treatment, biomarker turnaround, an acute oncology hotline, survivorship clinics, trial accrual: give the baseline, the change and the result. Cancer services are measured on pathway times, so this is a practical competence.

Anchor with the caveat: physicians, all other, have a BLS OEWS May 2025 median of $265,930 a year with the top 10% above $452,360, and that is a residual code covering many physician specialties rather than oncology alone. Then discuss structure — employed base plus production, academic salary with protected time, or private group with infusion participation — and ask for the group's actual figures.

In private community oncology, participation in infusion and pharmacy margin can be a substantial income component, while in a hospital-employed or academic model that revenue sits with the institution. Ask directly which model applies and whether any part flows to physician compensation. This single structural difference explains most of the variation between otherwise similar oncology offers.

Protected time for research or trial work with a defined percentage, malpractice with tail, advanced practice provider support, patient volume expectations and clinic template, call frequency including acute oncology cover, continuing medical education, and restrictive covenant terms. If research or trial accrual is part of the role, get the protected time and the support staff written into the contract rather than promised.